Serina Therapeutics
SER
36 hedge funds and large institutions have $8.21M invested in Serina Therapeutics in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 5 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
13% more capital invested
Capital invested by funds: $7.27M → $8.21M (+$934K)
0.02% more ownership
Funds ownership: 0.36% → 0.38% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
3% less funds holding
Funds holding: 37 → 36 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$447K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$199K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$89.8K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$61K |
| 5 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$9.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$171K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$33.5K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$22K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.52K |
SER Hedge Fund Activity: Q1 2021 in Review
36 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q1 2021, worth a combined $8.21M — up 13% from $7.27M a quarter earlier.
Fund positioning in SER was balanced in Q1 2021: 5 funds opened new positions, 5 closed out, 9 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $447K. The largest seller was Millennium Management, cutting an estimated $171K.
- 36 institutional investors held Serina Therapeutics (SER) as of Q1 2021, down from 37 in Q4 2020.
- Funds reported $8.21M of Serina Therapeutics stock for Q1 2021, up 13% quarter-over-quarter.
- 5 funds opened new Serina Therapeutics positions in Q1 2021 and 5 closed out, a net change of 0 holders.
- The largest Serina Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $447K added.
- The largest Serina Therapeutics seller in Q1 2021 was Millennium Management, an estimated $171K sold.
Based on aggregated 13F filings for Q1 2021.